Shionogi Sues To Block Another Generic Fortamet Challenge

Law360, New York (July 17, 2012, 3:23 PM EDT) -- Japanese pharmaceutical company Shionogi Inc. launched its latest bid to defend its Type 2 diabetes treatment Fortamet on Friday, suing Nostrum Pharmaceuticals LLC over its effort to market a generic version of the drug.

Shionogi and Watson Pharmaceuticals Inc. accused Nostrum of infringing two patents for Fortamet by filing an abbreviated new drug application with the U.S. Food and Drug Administration. Shionogi is the exclusive licensee of the patents, which is owned by Watson subsidiary Andrx Corp.

The suit comes as Shionogi is embroiled in a...
To view the full article, register now.